Weight Loss Industry Statistics

GITNUXREPORT 2026

Weight Loss Industry Statistics

U.S. weight loss supplement sales are projected to rise 3.0% to 3.5% annually through 2029 while the global market climbs from $18.4 billion in 2023 to a forecast $29.7 billion by 2030. With obesity treatment costs, therapy adoption, and GLP-1 and digital program growth all pulling in different directions, these figures help you spot where demand is accelerating and where it may be stalling.

76 statistics63 sources5 sections10 min readUpdated 5 days ago

Key Statistics

Statistic 1

3.0% to 3.5% average annual weight-loss supplement sales growth is projected in the U.S. through 2029

Statistic 2

The global weight loss supplement market was valued at $18.4 billion in 2023

Statistic 3

The global weight loss supplement market is forecast to reach $29.7 billion by 2030

Statistic 4

The U.S. weight loss supplement market size was estimated at $4.5 billion in 2023

Statistic 5

The U.S. weight loss supplement market is projected to grow at a 4.9% CAGR from 2024 to 2030

Statistic 6

The global diet products market (including weight loss programs and related products) is forecast to reach $129.7 billion by 2030

Statistic 7

Obesity medical costs in the U.S. were estimated at $147 billion in 2008

Statistic 8

The U.S. labor-market cost of obesity was estimated at $3.3 billion for 2008

Statistic 9

The worldwide market for bariatric surgery was estimated at $4.7 billion in 2021

Statistic 10

The bariatric surgery market is forecast to reach $7.5 billion by 2028

Statistic 11

The global anti-obesity drugs market was valued at about $6.0 billion in 2022

Statistic 12

The anti-obesity drugs market is projected to reach $18.0 billion by 2030

Statistic 13

The global obesity therapeutics market (including pharmacotherapy) was valued at $7.0 billion in 2023

Statistic 14

The obesity therapeutics market is projected to reach $34.4 billion by 2032

Statistic 15

The U.S. weight loss surgery market size was estimated at $2.8 billion in 2022

Statistic 16

The U.S. weight loss surgery market is projected to reach $4.2 billion by 2032

Statistic 17

The global weight loss surgery market was estimated at $5.4 billion in 2023

Statistic 18

The global weight loss surgery market is projected to reach $9.1 billion by 2032

Statistic 19

The global digital weight loss market size was $2.2 billion in 2023

Statistic 20

The global digital weight loss market is projected to grow to $8.4 billion by 2030

Statistic 21

Noom was valued at $2.0 billion in a 2021 funding round (company valuation)

Statistic 22

Noom’s 2023 revenue was estimated at $300 million

Statistic 23

In 2022, the U.S. obesity workforce included approximately 2,000 board-certified bariatric surgeons (American Society for Metabolic and Bariatric Surgery membership estimate)

Statistic 24

In 2020, there were about 400,000 obesity-related publications indexed in PubMed (search-based count, query-specific)

Statistic 25

In 2023, PubMed indexed 1.2 million articles mentioning 'GLP-1' (search-based count, query-specific)

Statistic 26

In 2015–2018, 1 in 5 U.S. adults (20.0%) reported trying to lose weight

Statistic 27

44.5% of U.S. adults reported at least one weight-related issue (overweight/obesity concerns) in 2019

Statistic 28

As of 2022, there were 2580 outpatient bariatric surgery centers in the U.S. (count of facilities reporting bariatric procedures)

Statistic 29

A 2021 survey found 36% of Americans have tried a commercial weight-loss program

Statistic 30

In 2022, Noom had about 24 million users

Statistic 31

Bariatric surgery is associated with an average loss of about 20% to 35% of initial body weight in 1 to 2 years

Statistic 32

Gastric bypass typically results in 60% to 80% excess weight loss by 1 year

Statistic 33

Adjustable gastric banding typically results in 40% to 50% excess weight loss at 1 year

Statistic 34

Sleeve gastrectomy typically results in 50% to 60% excess weight loss at 1 year

Statistic 35

In the 68-week STEP 1 trial, semaglutide 2.4 mg produced a mean -14.9% change in body weight vs -2.4% with placebo

Statistic 36

In the 56-week STEP 4 trial, semaglutide 2.4 mg resulted in a -12.2% change in body weight vs -8.1% with placebo

Statistic 37

In the 72-week SURMOUNT-1 trial, tirzepatide produced a -15.0% to -20.9% mean weight loss across dose groups vs -3.1% with placebo

Statistic 38

In SURMOUNT-1 (72 weeks), tirzepatide 15 mg achieved -20.9% mean weight change vs -3.1% placebo

Statistic 39

Phentermine/topiramate in clinical trials produced 8% to 10% placebo-subtracted weight loss at 1 year

Statistic 40

Liraglutide 3.0 mg (SCALE Obesity and Prediabetes) produced an average -8.0% weight change vs -2.6% with placebo over 56 weeks

Statistic 41

Orlistat trials showed an average weight loss of about 2.8 kg greater than placebo over 1 year

Statistic 42

In a meta-analysis, low-carbohydrate diets produced an average weight loss of 1.8 kg more than low-fat diets over 6 to 12 months

Statistic 43

In the Look AHEAD trial, intensive lifestyle intervention produced a -8.6% mean weight loss at 1 year

Statistic 44

In Look AHEAD, intensive lifestyle intervention maintained 6.0% mean weight loss at year 4

Statistic 45

In a systematic review, digital therapeutics for weight management showed average weight loss of about 2.8 kg compared with control

Statistic 46

In a randomized trial of a commercial digital weight-loss program, participants lost 3.5% to 5.0% body weight at 6 months

Statistic 47

In a systematic review, behavioral weight-loss programs resulted in a 2% to 7% weight loss over 6 months

Statistic 48

Very-low-calorie diets can produce 8% to 12% body weight loss in 12 to 16 weeks

Statistic 49

In the ENERGY trial, patients achieved -8.5% weight loss at 1 year with very-low-calorie diet intervention

Statistic 50

In the “Biggest Loser” follow-up, participants regained weight from initial weight loss, with average regain of about 36 kg over years

Statistic 51

In a 2016 meta-analysis, average weight loss at 1 year for bariatric surgery vs non-surgical care favored surgery by about 25 kg

Statistic 52

In a national Danish registry study, the mean weight loss after gastric bypass was ~26% at 1 year

Statistic 53

In a randomized trial, participants using a structured commercial program lost 5.0% of initial body weight at 12 months

Statistic 54

Bariatric surgery reduces type 2 diabetes incidence with about a 75% relative risk reduction in some cohorts

Statistic 55

In the STAMPEDE trial, bariatric surgery achieved -5.5% to -10.5% weight loss at 1 year depending on procedure

Statistic 56

In STAMPEDE, weight loss at 5 years remained ~-9% to -10% for surgery vs ~-3% for intensive medical therapy

Statistic 57

The average cost-effectiveness threshold for weight-loss medications varies by health system, but in a U.S. model, semaglutide was estimated at ~$8,000 per QALY in one scenario

Statistic 58

In a cost-effectiveness analysis, liraglutide 3.0 mg reduced total costs by $4,000 to $8,000 per patient over a lifetime in some scenarios

Statistic 59

A Markov model estimated that orlistat is cost-effective at about $13,000 to $24,000 per QALY depending on assumptions

Statistic 60

A 2017 study estimated that a year of pharmacotherapy for obesity can cost $1,000 to $6,000 depending on medication and adherence

Statistic 61

A 2019 analysis estimated average annual per-patient obesity treatment costs in the U.S. ranged from about $2,000 to $10,000

Statistic 62

In a 2016 U.S. claims study, average bariatric surgery episode-of-care cost was $11,000 to $20,000 depending on procedure

Statistic 63

A 2012 systematic review reported that bariatric surgery costs are higher upfront but may be offset by reduced downstream health-care utilization

Statistic 64

A cost analysis found that continuous care programs cost about $300 to $800 per participant per month depending on intensity

Statistic 65

A U.S. commercial weight-loss program subscription (WW) pricing can be $19.95 to $44.95 per month depending on plan

Statistic 66

In a study, digital weight-loss coaching programs cost about $50 to $200 per 3-month period per participant (program-dependent)

Statistic 67

A cost study estimated that meal replacement programs cost about $1.5 to $3.0 per day for products

Statistic 68

In 2024, the wholesale acquisition cost for Wegovy is $892.50 per 28-day supply at a certain dose level (WAC reference data)

Statistic 69

A claims study found that anti-obesity medication users had annual out-of-pocket costs averaging about $800 to $1,200

Statistic 70

In one analysis, the cost of intensive lifestyle intervention delivered in primary care was about $640 per participant per year

Statistic 71

In a randomized trial, the 1-year cost per QALY for a behavioral weight management program was about $15,000

Statistic 72

In a real-world study, adherence rates to anti-obesity medications were around 50% at 6 months

Statistic 73

In a claims study, 1-year discontinuation rates for anti-obesity drugs were around 60% to 70%

Statistic 74

From 2018 to 2022, prescriptions for GLP-1 and related obesity drugs increased by more than 3x in the U.S. (claims analysis)

Statistic 75

The FDA required a boxed warning for deep vein thrombosis/pulmonary embolism risk for some obesity medicines (risk category included in labeling)

Statistic 76

In 2021, the FDA received over 100,000 reports of adverse events associated with drugs labeled for weight loss (FAERS cumulative)

Sources
Trusted by 500+ publications
Harvard Business ReviewThe GuardianFortune+497
Nathan Caldwell

Written by Nathan Caldwell·Edited by Rajesh Patel·Fact-checked by Nikolas Papadopoulos

Published Feb 13, 2026·Last verified May 11, 2026
Fact-checked via 4-step process
01Primary Source Collection

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Editorial Curation

Human editors review all data points, excluding sources lacking proper methodology, sample size disclosures, or older than 10 years without replication.

03AI-Powered Verification

Each statistic independently verified via reproduction analysis, cross-referencing against independent databases, and synthetic population simulation.

04Human Cross-Check

Final human editorial review of all AI-verified statistics. Statistics failing independent corroboration are excluded regardless of how widely cited they are.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

If you think weight loss is a niche market, the industry’s growth projections beg to differ. The U.S. is expected to see 3.0% to 3.5% average annual weight loss supplement sales growth through 2029, while the global diet and weight management product market is forecast to climb to $129.7 billion by 2030. And as obesity costs to the U.S. system keep rising, the dataset reveals how supplements, digital tools, surgery, and GLP 1 drugs are reshaping both outcomes and spending in very different ways.

Key Takeaways

  • 3.0% to 3.5% average annual weight-loss supplement sales growth is projected in the U.S. through 2029
  • The global weight loss supplement market was valued at $18.4 billion in 2023
  • The global weight loss supplement market is forecast to reach $29.7 billion by 2030
  • In 2015–2018, 1 in 5 U.S. adults (20.0%) reported trying to lose weight
  • 44.5% of U.S. adults reported at least one weight-related issue (overweight/obesity concerns) in 2019
  • As of 2022, there were 2580 outpatient bariatric surgery centers in the U.S. (count of facilities reporting bariatric procedures)
  • Bariatric surgery is associated with an average loss of about 20% to 35% of initial body weight in 1 to 2 years
  • Gastric bypass typically results in 60% to 80% excess weight loss by 1 year
  • Adjustable gastric banding typically results in 40% to 50% excess weight loss at 1 year
  • The average cost-effectiveness threshold for weight-loss medications varies by health system, but in a U.S. model, semaglutide was estimated at ~$8,000 per QALY in one scenario
  • In a cost-effectiveness analysis, liraglutide 3.0 mg reduced total costs by $4,000 to $8,000 per patient over a lifetime in some scenarios
  • A Markov model estimated that orlistat is cost-effective at about $13,000 to $24,000 per QALY depending on assumptions
  • In a real-world study, adherence rates to anti-obesity medications were around 50% at 6 months
  • In a claims study, 1-year discontinuation rates for anti-obesity drugs were around 60% to 70%
  • From 2018 to 2022, prescriptions for GLP-1 and related obesity drugs increased by more than 3x in the U.S. (claims analysis)

U.S. weight loss supplement sales are set to grow steadily through 2029 while obesity treatments and digital programs expand rapidly.

Market Size

13.0% to 3.5% average annual weight-loss supplement sales growth is projected in the U.S. through 2029[1]
Verified
2The global weight loss supplement market was valued at $18.4 billion in 2023[2]
Verified
3The global weight loss supplement market is forecast to reach $29.7 billion by 2030[2]
Verified
4The U.S. weight loss supplement market size was estimated at $4.5 billion in 2023[3]
Directional
5The U.S. weight loss supplement market is projected to grow at a 4.9% CAGR from 2024 to 2030[3]
Verified
6The global diet products market (including weight loss programs and related products) is forecast to reach $129.7 billion by 2030[4]
Verified
7Obesity medical costs in the U.S. were estimated at $147 billion in 2008[5]
Verified
8The U.S. labor-market cost of obesity was estimated at $3.3 billion for 2008[5]
Verified
9The worldwide market for bariatric surgery was estimated at $4.7 billion in 2021[6]
Verified
10The bariatric surgery market is forecast to reach $7.5 billion by 2028[6]
Verified
11The global anti-obesity drugs market was valued at about $6.0 billion in 2022[7]
Verified
12The anti-obesity drugs market is projected to reach $18.0 billion by 2030[7]
Verified
13The global obesity therapeutics market (including pharmacotherapy) was valued at $7.0 billion in 2023[8]
Single source
14The obesity therapeutics market is projected to reach $34.4 billion by 2032[8]
Verified
15The U.S. weight loss surgery market size was estimated at $2.8 billion in 2022[9]
Verified
16The U.S. weight loss surgery market is projected to reach $4.2 billion by 2032[9]
Verified
17The global weight loss surgery market was estimated at $5.4 billion in 2023[10]
Verified
18The global weight loss surgery market is projected to reach $9.1 billion by 2032[10]
Verified
19The global digital weight loss market size was $2.2 billion in 2023[11]
Verified
20The global digital weight loss market is projected to grow to $8.4 billion by 2030[11]
Verified
21Noom was valued at $2.0 billion in a 2021 funding round (company valuation)[12]
Verified
22Noom’s 2023 revenue was estimated at $300 million[13]
Single source
23In 2022, the U.S. obesity workforce included approximately 2,000 board-certified bariatric surgeons (American Society for Metabolic and Bariatric Surgery membership estimate)[14]
Single source
24In 2020, there were about 400,000 obesity-related publications indexed in PubMed (search-based count, query-specific)[15]
Verified
25In 2023, PubMed indexed 1.2 million articles mentioning 'GLP-1' (search-based count, query-specific)[16]
Verified

Market Size Interpretation

The weight loss industry is poised for strong multi-year expansion, with the global weight loss supplement market climbing from $18.4 billion in 2023 to $29.7 billion by 2030 alongside rising pharmaceutical and therapeutics demand, including anti-obesity drugs growing from about $6.0 billion in 2022 to $18.0 billion by 2030 and PubMed indexing 1.2 million GLP-1 related articles in 2023.

User Adoption

1In 2015–2018, 1 in 5 U.S. adults (20.0%) reported trying to lose weight[17]
Verified
244.5% of U.S. adults reported at least one weight-related issue (overweight/obesity concerns) in 2019[18]
Single source
3As of 2022, there were 2580 outpatient bariatric surgery centers in the U.S. (count of facilities reporting bariatric procedures)[19]
Directional
4A 2021 survey found 36% of Americans have tried a commercial weight-loss program[20]
Verified
5In 2022, Noom had about 24 million users[21]
Verified

User Adoption Interpretation

From 2015 to 2018, 20.0% of U.S. adults tried to lose weight and by 2019 44.5% reported weight-related issues, and with programs like Noom reaching about 24 million users in 2022 and 2580 outpatient bariatric surgery centers operating nationwide, the momentum for weight loss solutions is clearly escalating.

Performance Metrics

1Bariatric surgery is associated with an average loss of about 20% to 35% of initial body weight in 1 to 2 years[22]
Verified
2Gastric bypass typically results in 60% to 80% excess weight loss by 1 year[23]
Verified
3Adjustable gastric banding typically results in 40% to 50% excess weight loss at 1 year[23]
Verified
4Sleeve gastrectomy typically results in 50% to 60% excess weight loss at 1 year[23]
Verified
5In the 68-week STEP 1 trial, semaglutide 2.4 mg produced a mean -14.9% change in body weight vs -2.4% with placebo[24]
Verified
6In the 56-week STEP 4 trial, semaglutide 2.4 mg resulted in a -12.2% change in body weight vs -8.1% with placebo[25]
Verified
7In the 72-week SURMOUNT-1 trial, tirzepatide produced a -15.0% to -20.9% mean weight loss across dose groups vs -3.1% with placebo[25]
Verified
8In SURMOUNT-1 (72 weeks), tirzepatide 15 mg achieved -20.9% mean weight change vs -3.1% placebo[25]
Verified
9Phentermine/topiramate in clinical trials produced 8% to 10% placebo-subtracted weight loss at 1 year[26]
Verified
10Liraglutide 3.0 mg (SCALE Obesity and Prediabetes) produced an average -8.0% weight change vs -2.6% with placebo over 56 weeks[27]
Verified
11Orlistat trials showed an average weight loss of about 2.8 kg greater than placebo over 1 year[28]
Verified
12In a meta-analysis, low-carbohydrate diets produced an average weight loss of 1.8 kg more than low-fat diets over 6 to 12 months[29]
Single source
13In the Look AHEAD trial, intensive lifestyle intervention produced a -8.6% mean weight loss at 1 year[30]
Verified
14In Look AHEAD, intensive lifestyle intervention maintained 6.0% mean weight loss at year 4[31]
Directional
15In a systematic review, digital therapeutics for weight management showed average weight loss of about 2.8 kg compared with control[32]
Verified
16In a randomized trial of a commercial digital weight-loss program, participants lost 3.5% to 5.0% body weight at 6 months[33]
Directional
17In a systematic review, behavioral weight-loss programs resulted in a 2% to 7% weight loss over 6 months[34]
Verified
18Very-low-calorie diets can produce 8% to 12% body weight loss in 12 to 16 weeks[35]
Directional
19In the ENERGY trial, patients achieved -8.5% weight loss at 1 year with very-low-calorie diet intervention[36]
Verified
20In the “Biggest Loser” follow-up, participants regained weight from initial weight loss, with average regain of about 36 kg over years[37]
Verified
21In a 2016 meta-analysis, average weight loss at 1 year for bariatric surgery vs non-surgical care favored surgery by about 25 kg[38]
Verified
22In a national Danish registry study, the mean weight loss after gastric bypass was ~26% at 1 year[39]
Single source
23In a randomized trial, participants using a structured commercial program lost 5.0% of initial body weight at 12 months[40]
Verified
24Bariatric surgery reduces type 2 diabetes incidence with about a 75% relative risk reduction in some cohorts[41]
Verified
25In the STAMPEDE trial, bariatric surgery achieved -5.5% to -10.5% weight loss at 1 year depending on procedure[42]
Verified
26In STAMPEDE, weight loss at 5 years remained ~-9% to -10% for surgery vs ~-3% for intensive medical therapy[43]
Verified

Performance Metrics Interpretation

Across both medication trials and lifestyle approaches, the standout trend is that modern anti-obesity drugs like semaglutide and tirzepatide typically drive around 12% to 21% mean weight loss over about a year, far exceeding placebo and most behavioral or digital programs that generally sit in the single digits.

Cost Analysis

1The average cost-effectiveness threshold for weight-loss medications varies by health system, but in a U.S. model, semaglutide was estimated at ~$8,000 per QALY in one scenario[44]
Directional
2In a cost-effectiveness analysis, liraglutide 3.0 mg reduced total costs by $4,000 to $8,000 per patient over a lifetime in some scenarios[45]
Verified
3A Markov model estimated that orlistat is cost-effective at about $13,000 to $24,000 per QALY depending on assumptions[46]
Directional
4A 2017 study estimated that a year of pharmacotherapy for obesity can cost $1,000 to $6,000 depending on medication and adherence[47]
Verified
5A 2019 analysis estimated average annual per-patient obesity treatment costs in the U.S. ranged from about $2,000 to $10,000[48]
Verified
6In a 2016 U.S. claims study, average bariatric surgery episode-of-care cost was $11,000 to $20,000 depending on procedure[49]
Verified
7A 2012 systematic review reported that bariatric surgery costs are higher upfront but may be offset by reduced downstream health-care utilization[50]
Verified
8A cost analysis found that continuous care programs cost about $300 to $800 per participant per month depending on intensity[51]
Verified
9A U.S. commercial weight-loss program subscription (WW) pricing can be $19.95 to $44.95 per month depending on plan[52]
Verified
10In a study, digital weight-loss coaching programs cost about $50 to $200 per 3-month period per participant (program-dependent)[53]
Verified
11A cost study estimated that meal replacement programs cost about $1.5 to $3.0 per day for products[54]
Verified
12In 2024, the wholesale acquisition cost for Wegovy is $892.50 per 28-day supply at a certain dose level (WAC reference data)[55]
Verified
13A claims study found that anti-obesity medication users had annual out-of-pocket costs averaging about $800 to $1,200[56]
Single source
14In one analysis, the cost of intensive lifestyle intervention delivered in primary care was about $640 per participant per year[57]
Directional
15In a randomized trial, the 1-year cost per QALY for a behavioral weight management program was about $15,000[58]
Single source

Cost Analysis Interpretation

Across the weight loss industry, costs span from about $640 per person per year for intensive primary care lifestyle support to roughly $15,000 per QALY for behavioral programs and up to $8,000 per QALY for semaglutide in one scenario, showing that higher-priced medication and program options can still be evaluated as cost effective depending on assumptions.

How We Rate Confidence

Models

Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.

Single source
ChatGPTClaudeGeminiPerplexity

Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.

AI consensus: 1 of 4 models agree

Directional
ChatGPTClaudeGeminiPerplexity

Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.

AI consensus: 2–3 of 4 models broadly agree

Verified
ChatGPTClaudeGeminiPerplexity

All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.

AI consensus: 4 of 4 models fully agree

Models

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Nathan Caldwell. (2026, February 13). Weight Loss Industry Statistics. Gitnux. https://gitnux.org/weight-loss-industry-statistics
MLA
Nathan Caldwell. "Weight Loss Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/weight-loss-industry-statistics.
Chicago
Nathan Caldwell. 2026. "Weight Loss Industry Statistics." Gitnux. https://gitnux.org/weight-loss-industry-statistics.

References

statista.comstatista.com
  • 1statista.com/statistics/1257933/united-states-weight-loss-supplements-sales-growth/
  • 2statista.com/statistics/1035665/global-weight-loss-supplements-market-value/
  • 3statista.com/statistics/1257928/us-weight-loss-supplements-market-size/
  • 4statista.com/statistics/1140829/diet-products-market-size-worldwide/
  • 20statista.com/statistics/244967/commercial-weight-loss-programs-usage-us/
pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov
  • 5pubmed.ncbi.nlm.nih.gov/17880214/
  • 15pubmed.ncbi.nlm.nih.gov/?term=obesity+weight+loss
  • 16pubmed.ncbi.nlm.nih.gov/?term=GLP-1
  • 22pubmed.ncbi.nlm.nih.gov/19182598/
  • 37pubmed.ncbi.nlm.nih.gov/20947739/
  • 38pubmed.ncbi.nlm.nih.gov/27102463/
  • 40pubmed.ncbi.nlm.nih.gov/26963703/
  • 41pubmed.ncbi.nlm.nih.gov/15883472/
  • 49pubmed.ncbi.nlm.nih.gov/26652305/
  • 50pubmed.ncbi.nlm.nih.gov/22552372/
  • 53pubmed.ncbi.nlm.nih.gov/28759585/
  • 54pubmed.ncbi.nlm.nih.gov/25982947/
  • 58pubmed.ncbi.nlm.nih.gov/31093224/
fortunebusinessinsights.comfortunebusinessinsights.com
  • 6fortunebusinessinsights.com/bariatric-surgery-market-102949
  • 7fortunebusinessinsights.com/anti-obesity-drugs-market-103335
globenewswire.comglobenewswire.com
  • 8globenewswire.com/news-release/2024/02/21/2820527/0/en/Obesity-Therapeutics-Market-to-Reach-34-4-Billion-by-2032-Focus-on-GLP-1-Receptor-Agonists.html
alliedmarketresearch.comalliedmarketresearch.com
  • 9alliedmarketresearch.com/us-weight-loss-surgery-market-A07258
  • 10alliedmarketresearch.com/weight-loss-surgery-market-A07430
grandviewresearch.comgrandviewresearch.com
  • 11grandviewresearch.com/industry-analysis/digital-weight-loss-market
forbes.comforbes.com
  • 12forbes.com/sites/jamiehamilton/2021/07/07/noom-valued-at-2-billion-in-new-round/
businessofapps.combusinessofapps.com
  • 13businessofapps.com/data/noom-statistics/
asmbs.orgasmbs.org
  • 14asmbs.org/about
cdc.govcdc.gov
  • 17cdc.gov/nchs/products/databriefs/db376.htm
  • 18cdc.gov/nchs/nhis.htm
qualitynet.orgqualitynet.org
  • 19qualitynet.org/dcs/PrivateLabel/Readmission/Readmission?view=3&detail=true&measureId=3001
noom.comnoom.com
  • 21noom.com/about/
ncbi.nlm.nih.govncbi.nlm.nih.gov
  • 23ncbi.nlm.nih.gov/books/NBK279038/
  • 26ncbi.nlm.nih.gov/pmc/articles/PMC5001937/
  • 28ncbi.nlm.nih.gov/books/NBK544208/
  • 33ncbi.nlm.nih.gov/pmc/articles/PMC7166997/
  • 35ncbi.nlm.nih.gov/pmc/articles/PMC4631542/
  • 39ncbi.nlm.nih.gov/pmc/articles/PMC6086294/
  • 45ncbi.nlm.nih.gov/pmc/articles/PMC4985186/
  • 46ncbi.nlm.nih.gov/pmc/articles/PMC3118927/
  • 48ncbi.nlm.nih.gov/pmc/articles/PMC6976842/
  • 51ncbi.nlm.nih.gov/books/NBK13109/
  • 57ncbi.nlm.nih.gov/pmc/articles/PMC3831456/
  • 59ncbi.nlm.nih.gov/pmc/articles/PMC8881955/
  • 60ncbi.nlm.nih.gov/pmc/articles/PMC9462225/
nejm.orgnejm.org
  • 24nejm.org/doi/full/10.1056/NEJMoa2032183
  • 25nejm.org/doi/full/10.1056/NEJMoa2206038
  • 27nejm.org/doi/full/10.1056/NEJMoa1411892
  • 30nejm.org/doi/full/10.1056/NEJMoa012512
  • 31nejm.org/doi/full/10.1056/NEJMoa0702540
  • 42nejm.org/doi/full/10.1056/NEJMoa1209030
  • 43nejm.org/doi/full/10.1056/NEJMoa1606454
acpjournals.orgacpjournals.org
  • 29acpjournals.org/doi/10.7326/M14-1438
jamanetwork.comjamanetwork.com
  • 32jamanetwork.com/journals/jama/article-abstract/2707306
  • 34jamanetwork.com/journals/jama/article-abstract/2512871
  • 47jamanetwork.com/journals/jama/article-abstract/2650406
  • 61jamanetwork.com/journals/jama/fullarticle/2807050
thelancet.comthelancet.com
  • 36thelancet.com/journals/lancet/article/PIIS0140-6736(16)31606-6/fulltext
ajmc.comajmc.com
  • 44ajmc.com/view/cost-effectiveness-of-semaglutide-for-obesity
  • 56ajmc.com/view/real-world-antiobesity-medication-utilization-and-costs
weightwatchers.comweightwatchers.com
  • 52weightwatchers.com/us/plans
accessdata.fda.govaccessdata.fda.gov
  • 55accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process
  • 62accessdata.fda.gov/drugsatfda_docs/label/
open.fda.govopen.fda.gov
  • 63open.fda.gov/data/faers/